These confirmed that IDO1 modulated the cells’ responses to DDP via the p53 pathway, and therefore it was worthwhile to test IDO1 inhibitors (small molecules or antibodies) in ovarian cancer. The gene discussed is TP53; the disease is ovarian carcinoma.